Biogen Inc. · NASDAQ:BIIB
Biogen — Biogen Idec — Q3 2006 Earnings Presentation
24 slides from Biogen's earnings presentation, Oct 31, 2006
Slide 1: Biogen Idec Q3 2006 Earnings Conference Call and Webcast
Biogen Idec Q3 2006 Earnings Conference Call and Webcast October 31, 2006 Fair Disclosure: Under "Reg FD," the SEC has set out a series of regulations regarding selective disclosure of material non-public information. In an effort to comply with these regulations, we believe it is important to state
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding expected future financial results, product development, and the potential for TYSABRI in MS. A number of risks and uncertainties could cause actual results to differ materially. For example, financial results and e
Slide 3: Q3 2006 Earnings Call Agenda
Q3 2006 Earnings Call Agenda Introduction Elizabeth Woo, VP Investor Relations Overview Jim Mullen, CEO Tysabri Launch Bob Hamm, SVP Neurology SBU Pipeline Update Burt Adelman, EVP Portfolio Strategy Financial Performance Peter Kellogg, CFO Q&A
Slide 4: Q3 2006 Overview
James Mullen Chief Executive Officer Q3 2006 Overview
Slide 5: Q3 2006 Highlights
Q3 2006 Highlights Successful Tysabri launch and initial rollout Over 2,200 patients being treated worldwide Pipeline progress Aiming to provide continuum of care for MS patients BG-12 for relapsing remitting MS, Galiximab for NHL & Lumiliximab for CLL Solid financial performance Strong revenue and
Slide 6: Tysabri Launch
Bob Hamm SVP, Neurology Strategic Business Unit Tysabri Launch
Slide 7: Tysabri Launch Progress
Tysabri Launch Progress July 2006 launch in both the EU and US European CHMP approval announced June 29, 2006 US FDA approval announced on June 5, 2006 Steady progress towards our goals Dosed over 2,200 individual patients with Tysabri worldwide to date In U.S.: ~4,500 TOUCH start forms, with ~1,700
Slide 8: Tysabri US Launch
Tysabri US Launch TOUCH Prescribing Program Goal of 2,000 to 2,500 practices/infusion centers trained by year end Represents access for >50% of indicated RRMS patients Rollout initially focused on Large MS centers Hospital based infusion sites associated with large neurology centers Majority of phys
Slide 9: Tysabri European Launch
Tysabri European Launch EU RiskMAP vs. US plan Both contain educational tools for patients and physicians and studies to better understand the risk of PML No mandatory registry required in EU Country specific launches As of Q3: Germany, UK, Ireland, Denmark, Sweden, Netherlands, Austria, Finland, No
Slide 10: Pipeline Update
Burt Adelman, MD EVP, Portfolio Strategy Pipeline Update
Slide 11: Pipeline Highlights
Pipeline Highlights Demonstrated expertise and execution Avonex remains leading MS therapy more than 10 years from launch Global launch of Tysabri, including re-launch in US, a major achievement Progress on clinical pipeline Ongoing development of pipeline BG-12 in relapsing remitting MS Anti-CD80 (
Slide 12: Multiple Sclerosis Portfolio Strategy
Multiple Sclerosis Portfolio Strategy Working assumption that a single drug will not work for every patient throughout the course of the disease Efficacy, safety, side effects and convenience all play a role Entire profile of drug balanced against the progression of the disease Patients will likely
Slide 13: Multiple Sclerosis Pipeline
Multiple Sclerosis Pipeline Partnered Programs Daclizumab Multiple sclerosis Phase 1 Market Avonex Tysabri Rituxan BG-12 Phase 2 Phase 3 Pre-Clin LINGO 1 Nogo-66 CDP323 MS Multiple sclerosis Multiple sclerosis Multiple sclerosis Multiple sclerosis MS MS Multiple sclerosis
Slide 14: Immunology Pipeline
Immunology Pipeline Partnered Programs LT Beta R Rheumatoid arthritis & Lupus (Ph 2) Phase 1 Market Rituxan Fumaderm Hu anti-CD20 Tysabri Psoriasis Crohn's disease Rheumatoid arthritis Phase 2 Phase 3 Pre-Clin BAFF Antag RA PAH Aviptadil Rheumatoid arthritis
Slide 15: Oncology Pipeline
Oncology Pipeline Partnered Programs NHL & CLL (Ph 3) Phase 1 Market Rituxan Zevalin Lumiliximab Galiximab NHL NHL CLL Phase 2 Phase 3 Pre-Clin Cripto HSP90 Inhib Solid tumors M200 Solid tumors Solid Anti-BR3 Solid
Slide 16: Financial Performance
Peter Kellogg Chief Financial Officer Financial Performance
Slide 17: Total Revenue Q3 2006
Total Revenue Q3 2006 Total revenues $703 million for Q3 2006, up 18% year-over-year Driven by growth in core franchises Avonex and Rituxan $596 $703 $0 $100 $200 $300 $400 $500 $600 $700 $800 Q3 2005 Q3 2006 Total Revenue (US$M) 18% increase over Q3 2005
Slide 18: Avonex Worldwide Sales Q3 2006
Avonex Worldwide Sales Q3 2006 Avonex sales $445 million for Q3 2006, up 19% year-over-year Strong ex-US growth a major driver $375 $445 $0 $100 $200 $300 $400 $500 Q3 2005 Q3 2006 Avonex Worldwide Sales (US$M) 19% increase over Q3 2005
Slide 19: Rituxan Sales and Profit Share Q3 2006
$182 $204 $0 $100 $200 $300 Q3 2005 Q3 2006 Rituxan Unconsolidated Joint Business Revenue (US$M) Rituxan Sales and Profit Share Q3 2006 US sales of Rituxan recognized by partner Genentech Rituxan US sales $509 million for Q3 2006, up 12% year-over-year Revenue from unconsolidated joint business to B
Slide 20: Tysabri Revenues
Tysabri Revenues Tysabri sales Total end user or in-market revenues $8.1 million $5.4 million of US end user sales $2.7 million of European end user sales, primarily from Germany Tysabri revenue Biogen Idec's Tysabri revenue was $19 million in Q3 2006 $5 million related to product sold in this quart
Slide 21: Executing External Growth Deals
Executing External Growth Deals BG-12 Product / Program Company HSP 90 oral & IV Aviptadil PML Therapy Daclizumab in MS M200 (volociximab) HuZAF (fontolizumab) CDP323
Slide 22: Summary
James Mullen Chief Executive Officer Summary
Slide 23: Q3 2006 Summary
Q3 2006 Summary Solid financial performance Strong revenue and earnings growth Increased full year 2006 guidance Successful Tysabri launch since late July with ~2,200 patients dosed ~4,500 TOUCH start forms, with ~1,700 of those patients infused 500 to 600 patients dosed in Europe ~1,000 practices/i
Slide 24: Questions & Answers
biogen idec Qllestions & Answers